Cytokine and chemokine modification by Toll-like receptor polymorphisms is associated with nasopharyngeal carcinoma

Cancer Science

Volumn 103, Issue 4, 2012, Pages 653-658

  Yang, Zhi Hui ^a   Dai, Qiong ^a   Gu, Ying Jiang ^a   Guo, Qing Xi ^a   Gong, Li ^a  

^a SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 8; MESSENGER RNA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHINESE; CONTROLLED STUDY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; UNDIFFERENTIATED CARCINOMA;

ADULT; CASE-CONTROL STUDIES; CHEMOKINES; CYTOKINES; FEMALE; HUMANS; MALE; NASOPHARYNGEAL NEOPLASMS; POLYMORPHISM, GENETIC; RNA, MESSENGER; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4;

EID: 84862801106     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02210.x     Document Type: Article

References (41)

1. Hsu MM. Clinical and pathological characteristics of nasopharyngeal carcinoma. Asian J Surg 1993; 16: 280-8.
2. Chen DL, Huang TB. A case-control study of risk factors of nasopharyngeal carcinoma. Cancer Lett 1997; 117: 17-22.
3. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002; 12: 421-9.
4. Zheng X, Yan L, Nilsson B et al. Epstein-Barr virus infection, salted fish and nasopharyngeal carcinoma. A case-control study in southern China. Acta Oncol 1994; 33: 867-72.
5. Thomas G, Jacobs KB, Yeager M et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: 310-5.
6. Yao JG, Gao LB, Liu YG et al. Genetic variation in interleukin-10 gene and risk of oral cancer. Clin Chim Acta 2008; 388: 84-8.
7. Wei YS, Lan Y, Luo B et al. Association of variants in the interleukin-27 and interleukin-12 gene with nasopharyngeal carcinoma. Mol Carcinog 2009; 48: 751-7.
8. Yang ZH, Dai Q, Zhong L et al. Association of IL-1 polymorphisms and IL-1 serum levels with susceptibility to nasopharyngeal carcinoma. Mol Carcinog 2011; 50: 208-14.
9. Sousa H, Breda E, Santos AM et al. Genetic risk markers for nasopharyngeal carcinoma in Portugal: tumor necrosis factor alpha-308G > A polymorphism. DNA Cell Biol 2011; 30: 99-103.
10. Santini D, Angeletti S, Ruzzo A et al. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol 2008; 154: 360-4.
11. Achyut BR, Ghoshal UC, Moorchung N et al. Association of Toll-like receptor-4 (Asp299Gly and Thr399Ileu) gene polymorphisms with gastritis and precancerous lesions. Hum Immunol 2007; 68: 901-7.
12. Lawrence T. Inflammation and cancer: a failure of resolution? Trends Pharmacol Sci 2007; 28: 162-5.
13. Garza-Gonzalez E, Bosques-Padilla FJ, Mendoza-Ibarra SI et al. Assessment of the Toll-like receptor 4 Asp299Gly, Thr399Ile and interleukin-8 -251 polymorphisms in the risk for the development of distal gastric cancer. BMC Cancer 2007; 7: 70.
14. Chen K, Huang J, Gong W et al. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 2007; 7: 1271-85.
15. Finberg RW, Wang JP, Kurt-Jones EA. Toll like receptors and viruses. Rev Med Virol 2007; 17: 35-43.
16. Trejo-de la O A, Torres J, Pérez-Rodríguez M et al. TLR4 single-nucleotide polymorphisms alter mucosal cytokine and chemokine patterns in Mexican patients with Helicobacter pylori-associated gastroduodenal diseases. Clin Immunol 2008; 129: 333-40.
17. Nieters A, Beckmann L, Deeg E et al. Gene polymorphisms in Toll-like receptors, interleukin-10 and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 2006; 7: 615-24.
18. Purdue MP, Lan Q, Wang SS et al. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis 2009; 30: 275-81.
19. Brennan B. Nasopharyngeal carcinoma. Orphanet J Rare Dis 2006; 1: 23.
20. John SW, Weitzner G, Rozen R et al. A rapid procedure for extracting genomic DNA from leukocytes. Nucleic Acids Res 1991; 19: 408.
21. Rigoli L, Di Bella C, Fedele F et al. TLR4 and NOD2/CARD15 genetic polymorphisms and their possible role in gastric carcinogenesis. Anticancer Res 2010; 30: 513-7.
22. Speletas M, Kalala F, Mitroulis I et al. TLR2 and TLR4 polymorphisms in familial Mediterranean fever. Hum Immunol 2009; 70: 750-3.
23. Nakagomi H, Dolcetti R, Bejarano MT et al. The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer 1994; 57: 240-4.
24. Eliopoulos AG, Stack M, Dawson CW et al. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kB pathway involving TNF receptor-associated factors. Oncogene 1997; 14: 2899-916.
25. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006; 4: 221-33.
26. Moss SF, Blaser MJ. Mechanisms of disease: inflammation and the origins of cancer. Nat Clin Pract Oncol 2005; 2: 90-7.
27. Bani MR, Garofalo A, Scanziani E et al. Effect of interleukin-1-beta on metastasis formation in different tumor systems. J Natl Cancer Inst 1991; 83: 119-23.
28. Yamashita U, Shirakawa F, Nakamura H. Production of interleukin 1 by adult T cell leukemia (ATL) cell lines. J Immunol 1987; 138: 3284-9.
29. Ito R, Kitadai Y, Kyo E et al. Interleukin 1α acts as an autocrine growth stimulator for human gastric carcinoma cells. Cancer Res 1993; 53: 4102-6.
30. Li BY, Mohanraj D, Olson MC et al. Human ovarian epithelial cancer cells cultured in vitro express both interleukin 1α and β genes. Cancer Res 1992; 52: 2248-52.
31. Quirk JT, Kupinski JM. Chronic infection, inflammation, and epithelial ovarian cancer. Med Hypotheses 2001; 57: 426-8.
32. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175-83.
33. Rollins BJ. Inflammatory chemokines in cancer growth and progression. Eur J Cancer 2006; 42: 760-7.
34. Younesi V, Nikzamir H, Yousefi M et al. Epstein Barr virus inhibits the stimulatory effect of TLR7/8 and TLR9 agonists but not CD40 ligand in human B lymphocytes. Microbiol Immunol 2010; 54: 534-41.
35. Gaudreault E, Fiola S, Olivier M et al. Epstein-Barr virus induces MCP-1 secretion by human monocytes via TLR2. J Virol 2007; 81: 8016-24.
36. Zheng SL, Augustsson-Balter K, Chang B et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res 2004; 64: 2918-22.
37. Chen YC, Giovannucci E, Lazarus R et al. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 2005; 65: 11771-8.
38. Cheng I, Plummer SJ, Casey G et al. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007; 16: 352-5.
39. Nischalke HD, Coenen M, Berger C et al. The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int J Cancer 2012; 130: 1470-5.
40. Huang YT, Sheen TS, Chen CL et al. Profile of cytokine expression in nasopharyngeal carcinomas: a distinct expression of interleukin 1 in tumor and CD41 T cells. Cancer Res 1999; 59: 1599-605.
41. Sredni B, Weil M, Khomenok G et al. Ammonium trichloro (dioxoethylene-o, o') tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res 2004; 64: 1843-52.